Equity Profile

CRVS

Corvus Pharmaceuticals, Inc.

Health CareBiotechnology$1.2B

Aug6Thu

Pre-Earnings Brief

UpcomingQ2-2026After Close5:00 PM EDT

Company Snapshot

Corvus Pharmaceuticals, Inc. is a biotechnology company focused on developing innovative therapies for cancer treatment....

Key Metrics to Watch

Revenue Growth

As a biotech firm, revenue growth is crucial to gauge the commercial success of its therapies.

N/A

EPS (Earnings Per Share)

EPS provides insight into the company's profitability and operational efficiency.

$-0.14

1 more metrics, Wall Street expectations, options signals, track record, and call prep available with Pro.

CRVS Q2-2026 Earnings Preview

Context

Company Snapshot

Corvus Pharmaceuticals, Inc. is a biotechnology company focused on developing innovative therapies for cancer treatment. Operating in the health care sector, it aims to address significant unmet medical needs through its research and development efforts.

Earnings Scorecard·Last 8Q

EPS Beat Streak

EPS Beat Rate

38%

Avg EPS Surprise

-58.69%

Avg Stock Reaction

-2.23%

Last Quarter Recap

In Q1-2026, Corvus reported an EPS of $-0.15, which was slightly below the estimate of $-0.14, leading to a stock decline of 5.57% the following day. The company continues to focus on advancing its pipeline of therapies.

Management Promises & Guidance

Expectations

Wall Street Expectations

Overall, there is uncertainty surrounding Corvus's upcoming earnings, especially given the recent trend of missing EPS estimates. Investors are keen to see if the company can turn around its performance this quarter.

Bull Case

If Corvus can report better-than-expected EPS and provide positive updates on its clinical trials, it could boost investor confidence and drive the stock higher.

Bear Case

Conversely, if the company misses EPS expectations again and fails to provide encouraging news on its pipeline, it may lead to further declines in stock price.

Key Metrics to Watch

Revenue Growth

N/A

As a biotech firm, revenue growth is crucial to gauge the commercial success of its therapies.

EPS (Earnings Per Share)

$-0.14

EPS provides insight into the company's profitability and operational efficiency.

Clinical Trial Updates

N/A

Updates on clinical trials can significantly impact investor sentiment and stock performance.

Expectations

Two Questions That Matter

The print will turn on these two things.

What will be the EPS for Q2-2026?

Given the company's recent history of EPS misses, this number will be crucial for investor sentiment.

What updates can management provide on ongoing clinical trials?

Positive news on clinical trials can significantly influence the stock price and investor confidence.

Edge

What the Street Is Missing

Why consensus could be wrong

The market may be overly pessimistic about Corvus's ability to meet or exceed EPS expectations, given its recent history of surprises.

Supporting Evidence

Options are pricing a 40.2% move, indicating that traders expect significant volatility.

The company has a 50% EPS beat rate historically, suggesting a chance of positive surprises.

Recent clinical trial results from peers have shown promise, which could bode well for Corvus.

Key Risk

If the EPS comes in better than $-0.12, it could shift sentiment dramatically.

Edge

Thesis-Break Levels

Pre-commit to what would confirm each case.

This quarter's performance is critical for Corvus as it attempts to regain investor confidence after a series of misses.

Bull Confirmed If

An EPS of $-0.12 or better, along with positive clinical trial updates.

Bear Confirmed If

An EPS worse than $-0.15 and no significant updates on clinical trials.

Pre-Earnings Positioning

Options Market

Implied Move

±40.2%

Historical Avg

±5.0%

Pricing rich

The options market is pricing in a significant potential move of over 40%, indicating high uncertainty about the earnings report.

Options are pricing ±40.2% while CRVS has averaged ±5.0% over the last 8 prints — setup is pricing rich.

Detail

ATM IV

0.8%

30d HV

96.0%

Calls (48K)P/C Ratio: 0.69Puts (16K)

Edge

Historical Setup Match

Cross-company pattern from 30 similar setups.

Prior-quarter miss + options pricing rich in Health Care

n=30

Fade rate: 13 of 29 (45%)

This setup has occurred 30 times across Health Care in the last 2 years. 13 of 29 faded and 16 held — no strong directional bias after the initial reaction. The average absolute 1-day move is 3.6%, with a raw directional average of -1.3% (modestly negative historical bias).

Preparation

Post-Print Playbook

Likely market behavior by outcome — not investment advice.

Beat & Raise

If Corvus beats expectations, history suggests a potential stock increase of around 2.4%, confirming a positive turnaround.

In-Line / Cautious

If results are in line with expectations, the stock may experience a muted reaction as investors await further guidance.

Miss

Should the company miss expectations again, history suggests a decline of about 6.87%, leading to increased skepticism about its future prospects.

Earnings Track Record

Preparation

What to Listen For

Call Prep

1Any updates on the progress of clinical trials.
2Management's commentary on cost management and operational efficiency.
3Insights into potential partnerships or collaborations.
4Details on market demand for their therapies.
5Any changes in guidance for future quarters.

See the full picture

AI-powered briefs, options data, and 20 quarters of history — everything you need before earnings.

No charge today · Auto-bills $8/mo after 7 days · Cancel anytime

More Earnings This Week

5 Reports

Danaos Corporation

Company Snapshot

Corvus Pharmaceuticals, Inc. is a biotechnology company focused on developing innovative therapies for cancer treatment....

Key Metrics to Watch

Revenue Growth

As a biotech firm, revenue growth is crucial to gauge the commercial success of its therapies.

N/A

EPS (Earnings Per Share)

EPS provides insight into the company's profitability and operational efficiency.

$-0.14

1 more metrics, Wall Street expectations, options signals, track record, and call prep available with Pro.

CRVS Q2-2026 Earnings Preview

Context

Company Snapshot

Earnings Scorecard·Last 8Q

EPS Beat Streak

EPS Beat Rate

38%

Avg EPS Surprise

-58.69%

Avg Stock Reaction

-2.23%

Last Quarter Recap

Management Promises & Guidance

Expectations

Wall Street Expectations

Bull Case

If Corvus can report better-than-expected EPS and provide positive updates on its clinical trials, it could boost investor confidence and drive the stock higher.

Bear Case

Conversely, if the company misses EPS expectations again and fails to provide encouraging news on its pipeline, it may lead to further declines in stock price.

Key Metrics to Watch

Revenue Growth

N/A

As a biotech firm, revenue growth is crucial to gauge the commercial success of its therapies.

EPS (Earnings Per Share)

$-0.14

EPS provides insight into the company's profitability and operational efficiency.

Clinical Trial Updates

N/A

Updates on clinical trials can significantly impact investor sentiment and stock performance.

Expectations

Two Questions That Matter

The print will turn on these two things.

What will be the EPS for Q2-2026?

Given the company's recent history of EPS misses, this number will be crucial for investor sentiment.

What updates can management provide on ongoing clinical trials?

Positive news on clinical trials can significantly influence the stock price and investor confidence.

Edge

What the Street Is Missing

Why consensus could be wrong

The market may be overly pessimistic about Corvus's ability to meet or exceed EPS expectations, given its recent history of surprises.

Supporting Evidence

Options are pricing a 40.2% move, indicating that traders expect significant volatility.

The company has a 50% EPS beat rate historically, suggesting a chance of positive surprises.

Recent clinical trial results from peers have shown promise, which could bode well for Corvus.

Key Risk

If the EPS comes in better than $-0.12, it could shift sentiment dramatically.

Edge

Thesis-Break Levels

Pre-commit to what would confirm each case.

This quarter's performance is critical for Corvus as it attempts to regain investor confidence after a series of misses.

Bull Confirmed If

An EPS of $-0.12 or better, along with positive clinical trial updates.

Bear Confirmed If

An EPS worse than $-0.15 and no significant updates on clinical trials.

Pre-Earnings Positioning

Options Market

Implied Move

±40.2%

Historical Avg

±5.0%

Pricing rich

The options market is pricing in a significant potential move of over 40%, indicating high uncertainty about the earnings report.

Options are pricing ±40.2% while CRVS has averaged ±5.0% over the last 8 prints — setup is pricing rich.

Detail

ATM IV

0.8%

30d HV

96.0%

Calls (48K)P/C Ratio: 0.69Puts (16K)

Edge

Historical Setup Match

Cross-company pattern from 30 similar setups.

Prior-quarter miss + options pricing rich in Health Care

n=30

Fade rate: 13 of 29 (45%)

Preparation

Post-Print Playbook

Likely market behavior by outcome — not investment advice.

Beat & Raise

If Corvus beats expectations, history suggests a potential stock increase of around 2.4%, confirming a positive turnaround.

In-Line / Cautious

If results are in line with expectations, the stock may experience a muted reaction as investors await further guidance.

Miss

Should the company miss expectations again, history suggests a decline of about 6.87%, leading to increased skepticism about its future prospects.

Earnings Track Record

Preparation

What to Listen For

Call Prep

1Any updates on the progress of clinical trials.
2Management's commentary on cost management and operational efficiency.
3Insights into potential partnerships or collaborations.
4Details on market demand for their therapies.
5Any changes in guidance for future quarters.